Influence of Escherichia coli lipopolysaccharide induced fever on the plasma kinetics of pazufloxacin in buffalo calves

S K SHARMA; ADITI ADITI; SHAH AHSAN UL HAQ

doi:10.56093/ijans.v84i2.37836

Authors

S K SHARMA Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141 004 India
ADITI ADITI Civil Veterinary Hospital, Binjo, Hoshiarpur, Punjab
SHAH AHSAN UL HAQ Civil Veterinary Hospital, Binjo, Hoshiarpur, Punjab

https://doi.org/10.56093/ijans.v84i2.37836

Keywords:

Buffalo calves, Pazufloxacin, Dosage regimen, Fever, Pharmacokinetics

Abstract

The pharmacokinetics of pazufloxacin was studied in healthy and febrile buffalo calves (5 mg/kg, IV). The fever was induced with Escherichia coli lipopolysaccharide. The drug concentration in plasma was detected by HPLC method. At 2.5 min the concentration of pazufloxacin in healthy and febrile animals were 17.8 0.6 µg/ml and 15.4±0.5 mg/ml, respectively and drug was detected up to 16 h. The distribution half-life of pazufloxacin increased from 0.09±0.01 h in healthy animals to 0.16±0.01 h in febrile animals. Drug distribution was altered by fever as febrile animals showed higher volume of distribution (1.35 0.09 L/ kg) higher than normal animal (1.03±0.06 L/kg). Total body clearances in healthy and febrile animals were 539.7±28.3 and 510.6±18.2 ml/kg/h, respectively. To maintain minimum therapeutic concentration of 0.1 µg/ml, a satisfactory dosage regimen of pazufloxacin in healthy and febrile buffalo calves would be 4.7 mg/kg and 4 mg/kg body weight, respectively, to be repeated at 12 h intervals.

Downloads

Download data is not yet available.

References

Chaudhary R K, Srivastava A K and Rampal S. 1999. Modification of the pharmacokinetics and dosage of cefuroxime by endotoxin- induced fever in buffalo calves. Veterinary Research Communications 23: 361–68.

Dardi M S, Sharma S K and Srivastava A K. 2005. Pharmacokinetics and dosage regimen of ceftriaxone in E Coli lipopolysaccharide induced fever in buffalo calves. Journal of Veterinary Science 6: 147–50.

Gibaldi M and Perrier D. 1982. Pharmacokinetics. Marcell Dekker Inc. New York.

Kumar N, Roy B K and Ranjan A. 2013. The influence of E. coli lipopolysaccharide induced fever on the plasma kinetics of ceftriaxone in Black-Bengal goats. Veterinarski Archiv 83(5): 479–80.

Nakata M, Yamashiro Y, Shimakura M, Takahata M, Minami S, Watanabe Y and Narita H. 1999. Pharmacokinetics of pazufloxacin mesilate in experimental animals. Japanese Journal of Chemotherapy 47: 65–75.

Pathania R and Sharma S K. 2010. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Research in Veterinary Science 89(1): 108–12.

Phapale P B, Lee H W, Kim S, Lim M, Kale D D, Lee J M, Park J H, Moon S and Yoon Y. 2010. Analysis of pazufloxacin mesilate in human plasma and urine by LC with fluorescence and UV detection and its application to pharmacokinetic study. Chromatographia 71: 101–06.

Raipuria M, Dumka V K and Sandhu H S. 2007. Plasma concentrations, pharmacokinetics and urinary excretion of gatifloxacin after single intravenous injection in buffalo calves. Veterinary Research Communications 31: 1013–20.

Sappal R, Chaudhary R K, Sandhu H S and Sidhu P K. 2009. Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis). Veterinary Research Communications 33: 659–67.

Toutain P L and Bousquet-Melou A. 2004. Volumes of distribution. Journal of Veterinary Pharmacology and Therapeutics 27: 441– 53.

Zhanel G G, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin A M, Gin A S, Rubinstein E and Hoban D J. 2006. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treatment in Respiratory Medicine 5: 437–65.